Potential risk for developing severe COVID-19 disease among anabolic steroid users

Flavio Cadegiani,1,2 Erica M Lin,3 Andy Goren,4 Carlos G Wambier 3

EXPRESSION OF CONCERN
Following concerns raised to BMJ, we are currently looking into the use of the drug reported in this case report (proxalutamide) and the circumstances surrounding its availability and license for use. While the investigation is ongoing, we would like to alert readers to this expression of concern.

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

ORCID iD
Carlos G Wambier http://orcid.org/0000-0002-4636-4489

1Adrenal and Hypertension Unit, Division of Endocrinology and Metabolism, Department of Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo (EPM/UNIFESP), São Paulo, São Paulo, Brazil
2Corpometria Institute, Brasilia, Distrito Federal, Brazil
3Department of Dermatology, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA
4Applied Biology Inc, Irvine, California, USA

Correspondence to
Dr Carlos G Wambier; carlos_wambier@brown.edu

Accepted 15 February 2021

To cite: Cadegiani F, Lin EM, Goren A, et al. BMJ Case Rep 2021;14:e241572. doi:10.1136/bcr-2021-241572